Kite's Yescarta CAR T-cell therapy demonstrates significantly longer overall survival versus standard of care as initial treatment of relapsed/refractory large B-cell lymphoma

Kite, a Gilead Company, announces detailed results from the overall survival (OS) analysis of the landmark Phase 3 ZUMA-7 study of Yescarta [axicabtagene ciloleucel (axi-cel)] CAR T-cell therapy compared with historical standard of care (SOC) as initial treatment in the curative setting for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Yescarta is the first treatment in nearly 30 years to demonstrate a significant improvement in survival in this patient population. The late-breaking data are being presented orally at the 2023 American Society of Clinical Oncology Annual Meeting (Abstract no LBA107) and published simultaneously in the New England Journal of Medicine. Yescarta's safety profile remains consistent with prior studies, and no new treatment-related deaths occurred since the primary EFS analysis. The primary EFS analysis showed that Grade 3 or higher adverse events (AEs) occurred in 91% of patients treated with axi-cel compared with 83% of those treated with SOC. The most common grade 3 or higher AEs were neutropenia (69% vs 41%, respectively), anaemia (30% vs 39%), and leukopenia (29% vs 22%). Original source: Gilead, website: http://www.gilead.com/, Copyright Gilead 2023.
research and development; anticancer drugs; axicabtagene ciloleucel; cell therapies; Yescarta; Gilead; [...]